Lung Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LNG039 MIFTS: 57	Lung Squamous Cell Carcinoma Categories: Cancer diseases, Respiratory diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma ¹¹ ¹⁴

Squamous Cell Carcinoma of Lung ¹¹ ⁷¹

Squamous Cell Lung Carcinoma ⁵ ¹⁶

Epidermoid Cell Carcinoma of the Lung ¹¹

Squamous Cell Lung Cancer ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3907

NCIt ⁴⁹ C3493

SNOMED-CT ⁶⁸ 254634000

EFO ¹⁶ EFO_0000708

UMLS ⁷¹ C0149782

Sources

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology: ¹¹ A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary: Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and lung cancer susceptibility 3. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Afatinib and Nedaplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotype is Decreased viability.

Sources

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 522)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	32.9	TUG1 TP53 SOX2-OT PIK3CA NFE2L2 KRAS
2	lung cancer susceptibility 3	32.3	TUG1 TP53 SFTA1P PIK3CA NPTN-IT1 NFE2L2
3	adenocarcinoma	32.3	TP53 PIK3CA KRAS HRAS EGFR
4	lung cancer	32.0	TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
5	small cell cancer of the lung	31.9	TUG1 TP53 PIK3CA EGFR CCAT2
6	lung benign neoplasm	31.6	TP53 KRAS HRAS EGFR
7	retinitis pigmentosa 11	31.4	TUG1 TP53 SOX2-OT PVT1 EGFR CCAT2
8	squamous cell carcinoma, head and neck	31.4	TP53 PIK3CA NFE2L2 HRAS EGFR
9	keratinizing squamous cell carcinoma	31.3	TP53 PIK3CA HRAS EGFR
10	large cell carcinoma	31.2	TP53 KRAS HRAS EGFR
11	exanthem	31.1	KRAS HRAS EGFR
12	esophagus squamous cell carcinoma	30.9	TUG1 SNHG1 PVT1 NPTN-IT1 MEG3 EGFR
13	esophageal cancer	30.9	TP53 PVT1 PIK3CA MEG3 KRAS HRAS
14	pleomorphic carcinoma	30.9	TP53 KRAS HRAS EGFR
15	papillary adenocarcinoma	30.9	TP53 KRAS HRAS
16	adenoma	30.8	TP53 PIK3CA KRAS HRAS
17	lung carcinoma in situ	30.8	TP53 KRAS HRAS EGFR
18	rectal benign neoplasm	30.8	TP53 PIK3CA KRAS HRAS EGFR
19	signet ring cell adenocarcinoma	30.8	TP53 KRAS HRAS
20	large cell neuroendocrine carcinoma	30.8	TP53 KRAS HRAS EGFR
21	lung adenoma	30.8	TP53 KRAS HRAS EGFR
22	rectum adenocarcinoma	30.8	TP53 PIK3CA KRAS HRAS EGFR
23	colorectal adenocarcinoma	30.8	TP53 PIK3CA KRAS HRAS EGFR
24	breast adenocarcinoma	30.8	TP53 PIK3CA KRAS HRAS EGFR
25	bronchiolo-alveolar adenocarcinoma	30.8	TP53 KRAS HRAS EGFR
26	colonic benign neoplasm	30.8	TP53 PIK3CA KRAS HRAS EGFR
27	lung sarcomatoid carcinoma	30.8	KRAS HRAS EGFR
28	laryngeal benign neoplasm	30.8	TP53 PIK3CA EGFR
29	gastrointestinal stromal tumor	30.8	TP53 PIK3CA KRAS HRAS EGFR
30	skin melanoma	30.8	TP53 PIK3CA KRAS HRAS
31	adenoid cystic carcinoma	30.8	TP53 PIK3CA KRAS HRAS EGFR
32	lung non-squamous non-small cell carcinoma	30.8	KRAS HRAS EGFR
33	thyroid gland anaplastic carcinoma	30.8	TP53 PIK3CA HRAS EGFR
34	head and neck cancer	30.8	TP53 PIK3CA KRAS HRAS EGFR
35	skin squamous cell carcinoma	30.8	TP53 HRAS EGFR
36	rectum cancer	30.8	TP53 KRAS HRAS EGFR
37	pleomorphic rhabdomyosarcoma	30.8	TP53 PIK3CA HRAS
38	cholangiocarcinoma	30.8	TUG1 TP53 SOX2-OT PIK3CA KRAS EGFR
39	malignant pleural mesothelioma	30.8	TP53 PVT1 HRAS EGFR
40	kidney cancer	30.8	TP53 PVT1 PIK3CA MEG3 EGFR
41	colon adenocarcinoma	30.8	TP53 PIK3CA KRAS HRAS EGFR
42	diffuse gastric cancer	30.8	TP53 PIK3CA KRAS
43	intrahepatic cholangiocarcinoma	30.8	TUG1 TP53 KRAS HRAS EGFR CCAT2
44	gastric adenocarcinoma	30.8	TP53 PIK3CA KRAS HRAS
45	wilms tumor 1	30.8	TP53 MEG3 KRAS HRAS EGFR
46	glioma	30.8	TP53 PVT1 PIK3CA MEG3 EGFR CCAT2
47	glioblastoma	30.8	TUG1 TP53 PIK3CA MEG3 KRAS HRAS
48	neuroblastoma	30.7	TP53 SNHG1 PIK3CA NFE2L2 MEG3 HRAS
49	rhabdomyosarcoma	30.7	TP53 PIK3CA KRAS HRAS EGFR
50	nasopharyngeal carcinoma	30.7	TP53 PVT1 PIK3CA NPTN-IT1 MEG3 EGFR

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.68	EGFR HRAS KRAS PIK3CA
2	Decreased viability	GR00055-A-2	9.68	EGFR HRAS KRAS PIK3CA
3	Decreased viability	GR00055-A-3	9.68	KRAS
4	Decreased viability	GR00106-A-0	9.68	KRAS
5	Decreased viability	GR00221-A-1	9.68	EGFR HRAS KRAS PIK3CA
6	Decreased viability	GR00221-A-2	9.68	HRAS KRAS PIK3CA
7	Decreased viability	GR00221-A-3	9.68	HRAS
8	Decreased viability	GR00221-A-4	9.68	EGFR PIK3CA
9	Decreased viability	GR00301-A	9.68	KRAS
10	Decreased viability	GR00381-A-1	9.68	KRAS
11	Decreased viability	GR00402-S-2	9.68	PIK3CA

Sources

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Afatinib

Approved

Phase 4

439081-18-2, 850140-72-6

53445376 10184653

Nedaplatin

Approved, Investigational

Phase 4

95734-82-0

Rivoceranib

Investigational

Phase 4

811803-05-1

11315474

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Durvalumab

Approved, Investigational

Phase 2, Phase 3

1428935-60-7

Palbociclib

Approved, Investigational

Phase 2, Phase 3

571190-30-2

5330286

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Ipilimumab

Approved

Phase 3

477202-00-9

Cetuximab

Approved

Phase 3

205923-56-4

Erlotinib

Approved, Investigational

Phase 2, Phase 3

183319-69-9, 183321-74-6

176870

Iniparib

Investigational

Phase 3

160003-66-7

9796068

Rilotumumab

Investigational

Phase 2, Phase 3

872514-65-3

Endostar protein

Phase 3

Endostatins

Phase 3

Antimetabolites

Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 3

Shark Cartilage

Phase 3

Angiogenesis Inhibitors

Phase 3

Immunoglobulin G

Phase 3

Endothelial Growth Factors

Phase 3

Mitogens

Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Protein Kinase Inhibitors

Phase 2, Phase 3

Immunoglobulins, Intravenous

Phase 2, Phase 3

Immunoglobulins

Phase 2, Phase 3

Antibodies, Monoclonal

Phase 2, Phase 3

Antibodies

Phase 2, Phase 3

Treosulfan

Approved, Investigational

Phase 2

299-75-2

9296

Clarithromycin

Approved

Phase 2

81103-11-9

84029

Pioglitazone

Approved, Investigational

Phase 2

111025-46-8

4829

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Talazoparib

Approved, Investigational

Phase 2

1207456-01-6

135565082

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

Ceritinib

Approved

Phase 2

1032900-25-6

57379345

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Auranofin

Approved, Investigational

Phase 1, Phase 2

34031-32-8

6918453 16667669 70788951

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4

Coenzyme M

Approved, Investigational

Phase 1, Phase 2

3375-50-6

598 23662354

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Interventional clinical trials:

(show top 50) (show all 113)

#	Name	Status	NCT ID	Phase	Drugs
1	Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above	Unknown status	NCT03725423	Phase 4	Apatinib
2	An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation	Unknown status	NCT04132102	Phase 4	Afatinib
3	Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study	Completed	NCT02088515	Phase 4	Nedaplatin;Cisplatin;Docetaxel
4	Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma	Unknown status	NCT01947062	Phase 3	Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
5	The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.	Unknown status	NCT02283476	Phase 3	Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
6	Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study	Unknown status	NCT02643407	Phase 3	Docetaxel;Nedaplatin;Cisplatin
7	A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer	Unknown status	NCT03866993	Phase 3	Paclitaxel;Carboplatin;Placebo
8	A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study)	Completed	NCT02766335	Phase 2, Phase 3	Docetaxel
9	A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Completed	NCT02965378	Phase 2, Phase 3	Docetaxel;FGFR Inhibitor AZD4547
10	A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Completed	NCT02785939	Phase 2, Phase 3	Docetaxel;Palbociclib
11	A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer	Completed	NCT00020709	Phase 3	cisplatin;docetaxel;etoposide;gefitinib
12	Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer	Completed	NCT00005838	Phase 3	shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
13	A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG	Completed	NCT00002852	Phase 3	paclitaxel;carboplatin
14	A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer	Completed	NCT00049543	Phase 3	gefitinib
15	Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)	Completed	NCT01082549	Phase 3	gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
16	A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)	Active, not recruiting	NCT02785952	Phase 3
17	A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	NCT00946712	Phase 3	Carboplatin;Paclitaxel
18	Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)	Active, not recruiting	NCT03150875	Phase 3	IBI308;Docetaxel
19	A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Terminated	NCT02926638	Phase 2, Phase 3	Erlotinib Hydrochloride
20	Photodynamic Therapy for the Prevention of Lung Cancer (PEARL)	Withdrawn	NCT03346304	Phase 2, Phase 3
21	An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer	Unknown status	NCT02009605	Phase 2	Icotinib
22	A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy	Unknown status	NCT01969955	Phase 2	nanoparticle albumin-bound paclitaxel
23	Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial	Unknown status	NCT01660399	Phase 2	Boanmycin;Docetaxel
24	Phase II Study of Afatinib Plus Chemotherapy in Patients With Esophageal and Lung Squamous Cell Carcinoma	Unknown status	NCT03486509	Phase 2	Afatinib
25	A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma	Unknown status	NCT02428764	Phase 2	Nimotuzumab;Gemcitabine;Carboplatin
26	A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers	Unknown status	NCT02583542	Phase 1, Phase 2	AZD2014;AZD6244
27	A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure	Unknown status	NCT02852083	Phase 2	Pioglitazone;nivolumab;Treosulfan;Clarithromycin
28	SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)	Unknown status	NCT03823625	Phase 2	Nivolumab plus Ipilimumab;Platinum-based chemotherapy plus Nivolumab
29	A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer	Unknown status	NCT02787473	Phase 2	pemetrexed;cisplatin;docetaxel
30	A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer	Unknown status	NCT01494415	Phase 2	Paclitaxel for Injection（Albumin Bound）;carboplatin
31	A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Squamous Non Small Cell Lung Carcinoma (sqNSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.	Unknown status	NCT03827850	Phase 2	ERDAFITINIB
32	A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers	Unknown status	NCT02423590	Phase 2	Apatorsen (OGX-427);Gemcitabine;Carboplatin
33	A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung	Completed	NCT01236716	Phase 2	Albumin paclitaxel plus carboplatin;Gemcitabine plus carboplatin
34	A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations	Completed	NCT02417701	Phase 2	Sapanisertib
35	A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
36	A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)	Completed	NCT02785913	Phase 2	Taselisib
37	A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Completed	NCT03377556	Phase 2	Talazoparib
38	A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)	Completed	NCT03574753	Phase 2	ABBV-399
39	A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)	Completed	NCT03373760	Phase 2
40	A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC)	Completed	NCT02276027	Phase 2	BYL719;INC280;LDK378;MEK162
41	Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy	Completed	NCT01294306	Phase 2	Akt Inhibitor MK2206;Erlotinib Hydrochloride
42	A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung	Completed	NCT02920476	Phase 2	TAS-102
43	A Prospective Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer	Completed	NCT02577341	Phase 2	Nimotuzumab;docetaxel and cisplatin
44	FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens	Completed	NCT01948141	Phase 2	nintedanib
45	AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer	Completed	NCT00585377	Phase 2	Bevacizumab and Erlotinib
46	A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination With Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis	Completed	NCT00387374	Phase 2	paclitaxel;carboplatin
47	Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2	Completed	NCT00087412	Phase 2	erlotinib hydrochloride
48	A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer	Completed	NCT00368992	Phase 2	paclitaxel
49	ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study	Completed	NCT00040794	Phase 2	paclitaxel;carboplatin;gefitinib
50	A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2	Completed	NCT00118183	Phase 2	docetaxel;bortezomib

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Sources

Genetic Tests for Lung Squamous Cell Carcinoma

Sources

Anatomical Context for Lung Squamous Cell Carcinoma

Organs/tissues related to Lung Squamous Cell Carcinoma:

MalaCards : Lung, T Cells, Lymph Node, Endothelial, Bone Marrow, Brain, Bronchial Epithelium

Sources

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 3543)

#	Title	Authors	PMID	Year
1	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. ⁶² ⁵	Liao RG...Hammerman PS	23786770	2013
2	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. ⁶² ⁵	Hammerman PS...Meyerson M	22328973	2011
3	EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. ⁶² ⁵	Faoro L...Salgia R	20360610	2010
4	Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. ⁶² ⁵	Santos E...Barbacid M	6695174	1984
5	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
6	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. ⁵	Huang MH...Yang JC	23102728	2013
7	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. ⁵	Ramalingam SS...Boyer M	22753918	2012
8	Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. ⁵	Foster JM...Loggie BW	20942962	2010
9	LKB1 modulates lung cancer differentiation and metastasis. ⁵	Ji H...Wong KK	17676035	2007
10	Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. ⁵	Forcet C...Billaud M	15800014	2005
11	[The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report]. ⁵³ ⁶²	Kosacka M...Jankowska R	20369739	2010
12	Metabolic targets of cardiac hormones' therapeutic anti-cancer effects. ⁵³ ⁶²	Vesely DL	20030620	2010
13	Cardiac and renal hormones: anticancer effects in vitro and in vivo. ⁵³ ⁶²	Vesely DL	19092678	2009
14	[The prognostic value of cytokeratin 19 expression in non-small cell lung cancer]. ⁵³ ⁶²	Kosacka M...Jankowska R	18080980	2007
15	[Transcription TIMP3, DAPk1 and AKR1B10 genes in squamous cell lung cancer]. ⁵³ ⁶²	Mashkova TD...Kiselev LL	17209433	2006
16	Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? ⁵³ ⁶²	Vesely DL	16487258	2006
17	Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. ⁵³ ⁶²	Almasi CE...Pappot H	15893003	2005
18	Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. ⁵³ ⁶²	Tas F...Saip P	11277326	2000
19	Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. ⁵³ ⁶²	Pappot H...Grondahl-Hansen J	9291807	1997
20	Production of cytokeratin 19 fragment by human squamous lung cancer cell lines. ⁵³ ⁶²	Satoh H...Kamma H	9160842	1997
21	A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. ⁵³ ⁶²	Kim YC...Bom HS	8882476	1996
22	Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA. ⁵³ ⁶²	Berzinec P...Arpasova M	8841502	1996
23	Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. ⁵³ ⁶²	Satoh H...Hasegawa S	7536317	1995
24	Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. ⁵³ ⁶²	Buccheri G...Vola F	8069601	1993
25	Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer. ⁵³ ⁶²	Kukreja SC...Martin TJ	2361475	1990
26	Histological types of lung cancer attributable to fine particulate, smoking, and genetic susceptibility. ⁶²	Wang X...Lin H	36334679	2023
27	Pan-cancer analysis of Chromobox (CBX) genes for prognostic significance and cancer classification. ⁶²	Naqvi AAT...Hassan MI	36183965	2023
28	The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer. ⁶²	Partynska A...Dziegiel P	36456139	2022
29	PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model. ⁶²	Dwyer-Nield LD...Keith RL	35830207	2022
30	Diet-wide association study of 92 foods and nutrients and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study. ⁶²	Heath AK...Tsilidis KK	35830197	2022
31	A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer. ⁶²	Machida M...Aisaka H	36464708	2022
32	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. ⁶²	Kasai T...Nakayama M	36241930	2022
33	Efficacy of direct oral anticoagulant for renal infarction due to pulmonary vein stump thrombosis after left pneumonectomy. ⁶²	Iijima Y...Uramoto H	36459304	2022
34	Influence of ABO blood group on susceptibility to different pathological types of lung cancer: a retrospective study. ⁶²	Yang H...Zhong N	36464709	2022
35	Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients. ⁶²	Liu X...Duan C	36456645	2022
36	Construction of a prognostic model for lung squamous cell carcinoma based on immune-related genes. ⁶²	Pu J...Song Q	36455238	2022
37	Dysregulated Th1 cells in lung squamous cell carcinoma. ⁶²	Wang J...Ren X	35686499	2022
38	FDG PET/CT in Isolated Nasal Cavity Metastasis From Squamous Cell Lung Cancer. ⁶²	Zhang J...Wang Y	35961364	2022
39	Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center. ⁶²	Chen YC...Lee CC	36469189	2022
40	Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma. ⁶²	Fang Y...Ouyang S	36463240	2022
41	Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report. ⁶²	Nishimura R...Ohe Y	36453575	2022
42	Solitary metachronous splenic metastasis related with lung squamous cell carcinoma: A case report. ⁶²	Xuan H...Yao Y	36464590	2022
43	ASO Visual Abstract: S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial. ⁶²	Takamochi K...Suzuki K	36209323	2022
44	S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial. ⁶²	Takamochi K...Advanced Clinical Trial Chest Surgery Group (ACTG)	36097299	2022
45	ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma. ⁶²	Gao Y...Han M	36418641	2022
46	Roles of H19/miR-29a-3p/COL1A1 axis in COE-induced lung cancer. ⁶²	Zhang H...Zhao Y	36150622	2022
47	Squamous cell lung cancer: Current landscape and future therapeutic options. ⁶²	Lau SCM...Wong KK	36270277	2022
48	Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. ⁶²	Imamura K...Sakagami T	36430217	2022
49	CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma. ⁶²	Ma Y...Wu N	35733338	2022
50	Minichromosome maintenance gene family: potential therapeutic targets and prognostic biomarkers for lung squamous cell carcinoma. ⁶²	Yang X...Ou C	36445337	2022

Sources

Genes for Lung Squamous Cell Carcinoma

Genes related to Lung Squamous Cell Carcinoma (2 elite genes):

(show top 50) (show all 100)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	432.57	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	20942962 1111234672 22753918 (more) 23102728 26619011
2	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	432.08	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	6695174 26619011
3	SOX2-OT	SOX2 Overlapping Transcript	RNA Gene	155.86	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24927902 26136768 28076325
4	PVT1	Pvt1 Oncogene	RNA Gene	155.23	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26928440 27797003
5	SNHG1	Small Nucleolar RNA Host Gene 1	RNA Gene	155	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28415044
6	TUG1	Taurine Up-Regulated 1	Protein Coding	154.71	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28076325
7	BRD3OS	BRD3 Opposite Strand	Protein Coding	154.63	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28949095
8	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	154.51	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28076325
9	LINC01133	Long Intergenic Non-Protein Coding RNA 1133	RNA Gene	154.41	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25908174
10	TERC	Telomerase RNA Component	RNA Gene	154.27	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26928440
11	CCAT2	Colon Cancer Associated Transcript 2	RNA Gene	154.26	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28076325
12	CDKN2A-DT	CDKN2A Divergent Transcript	RNA Gene	153.97	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27903974
13	LINC01600	Long Intergenic Non-Protein Coding RNA 1600	RNA Gene	150	Experimental evidence: Expression ³⁷	27903974
14	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Regulation ³⁷	28076325
15	NPTN-IT1	NPTN Intronic Transcript 1	RNA Gene	150	Experimental evidence: Expression ³⁷	23395002
16	SFTA1P	Surfactant Associated 1, LncRNA	Pseudogene	150	Experimental evidence: Regulation ³⁷	29228625
17	TP53	Tumor Protein P53	Protein Coding	48.25	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
18	NFE2L2	NFE2 Like BZIP Transcription Factor 2	Protein Coding	47.22	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
19	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	47.14	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
20	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	39.14	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
21	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	38.3	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
22	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	37.79	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26619011
23	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	37.65	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	23786770
24	EPHA2	EPH Receptor A2	Protein Coding	37.03	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	20360610
25	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	32.06	Likely pathogenic ⁵ DISEASES inferred ¹⁴
26	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	31.73	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
27	PTEN	Phosphatase And Tensin Homolog	Protein Coding	31.55	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
28	STK11	Serine/Threonine Kinase 11	Protein Coding	31.36	Likely pathogenic ⁵ DISEASES inferred ¹⁴	15800014 17676035
29	DDR2	Discoidin Domain Receptor Tyrosine Kinase 2	Protein Coding	31.12	Likely pathogenic ⁵ DISEASES inferred ¹⁴	22328973
30	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	30.56	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
31	EP300	E1A Binding Protein P300	Protein Coding	30.06	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
32	CREBBP	CREB Binding Protein	Protein Coding	29.81	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
33	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	29.78	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
34	B2M	Beta-2-Microglobulin	Protein Coding	29.58	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
35	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	29.39	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
36	PPP6C	Protein Phosphatase 6 Catalytic Subunit	Protein Coding	27.77	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
37	EGFR-AS1	EGFR Antisense RNA 1	RNA Gene	25	Likely pathogenic ⁵	23102728 22753918
38	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	26619011
39	MED12	Mediator Complex Subunit 12	Protein Coding	25	Likely pathogenic ⁵	26619011
40	KEAP1	Kelch Like ECH Associated Protein 1	Protein Coding	22.35	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
41	CDH10	Cadherin 10	Protein Coding	21.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
42	KMT2D	Lysine Methyltransferase 2D	Protein Coding	21.01	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
43	NSD1	Nuclear Receptor Binding SET Domain Protein 1	Protein Coding	20.46	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
44	RASA1	RAS P21 Protein Activator 1	Protein Coding	19.96	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
45	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	19.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
46	KRT19	Keratin 19	Protein Coding	13.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9160842 8882476 18080980
47	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	12.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	12.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	FAT1	FAT Atypical Cadherin 1	Protein Coding	12.32	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
50	ZNF750	Zinc Finger Protein 750	Protein Coding	12.15	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)

Sources

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

⁵ (show top 50) (show all 329)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	EGFR	NM_005228.5(EGFR):c.2492G>A (p.Arg831His)	SNV	Pathogenic	560007	rs150036236	GRCh37: 7:55259434-55259434 GRCh38: 7:55191741-55191741
2	KRAS	NM_004985.5(KRAS):c.34G>C (p.Gly12Arg)	SNV	Pathogenic	12579	rs121913530	GRCh37: 12:25398285-25398285 GRCh38: 12:25245351-25245351
3	TP53	NM_000546.6(TP53):c.733G>C (p.Gly245Arg)	SNV	Likely Pathogenic	376604	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
4	TP53	NM_000546.6(TP53):c.641A>G (p.His214Arg)	SNV	Likely Pathogenic	376615	rs1057519992	GRCh37: 17:7578208-7578208 GRCh38: 17:7674890-7674890
5	TP53	NM_000546.6(TP53):c.808T>A (p.Phe270Ile)	SNV	Likely Pathogenic	376596	rs1057519988	GRCh37: 17:7577130-7577130 GRCh38: 17:7673812-7673812
6	CDKN2A	NM_000077.5(CDKN2A):c.239G>A (p.Arg80Gln)	SNV	Likely Pathogenic	376385	rs1057519883	GRCh37: 9:21971119-21971119 GRCh38: 9:21971120-21971120
7	TP53	NM_000546.6(TP53):c.841G>C (p.Asp281His)	SNV	Likely Pathogenic	376588	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
8	TP53	NM_000546.6(TP53):c.487T>C (p.Tyr163His)	SNV	Likely Pathogenic	376680	rs786203436	GRCh37: 17:7578443-7578443 GRCh38: 17:7675125-7675125
9	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Likely Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
10	TP53	NM_000546.6(TP53):c.725G>A (p.Cys242Tyr)	SNV	Likely Pathogenic	12354	rs121912655	GRCh37: 17:7577556-7577556 GRCh38: 17:7674238-7674238
11	STK11	NM_000455.5(STK11):c.1060T>C (p.Phe354Leu)	SNV	Likely Pathogenic	376711	rs1057520018	GRCh37: 19:1223123-1223123 GRCh38: 19:1223124-1223124
12	TP53	NM_000546.6(TP53):c.658T>A (p.Tyr220Asn)	SNV	Likely Pathogenic	376688	rs530941076	GRCh37: 17:7578191-7578191 GRCh38: 17:7674873-7674873
13	TP53	NM_000546.6(TP53):c.808T>G (p.Phe270Val)	SNV	Likely Pathogenic	376598	rs1057519988	GRCh37: 17:7577130-7577130 GRCh38: 17:7673812-7673812
14	FGFR3	NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys)	SNV	Likely Pathogenic	16339	rs121913483	GRCh37: 4:1803568-1803568 GRCh38: 4:1801841-1801841
15	TP53	NM_000546.6(TP53):c.838A>G (p.Arg280Gly)	SNV	Likely Pathogenic	376658	rs753660142	GRCh37: 17:7577100-7577100 GRCh38: 17:7673782-7673782
16	TP53	NM_000546.6(TP53):c.536A>C (p.His179Pro)	SNV	Likely Pathogenic	376611	rs1057519991	GRCh37: 17:7578394-7578394 GRCh38: 17:7675076-7675076
17	TP53	NM_000546.6(TP53):c.527G>A (p.Cys176Tyr)	SNV	Likely Pathogenic	186451	rs786202962	GRCh37: 17:7578403-7578403 GRCh38: 17:7675085-7675085
18	TP53	NM_000546.6(TP53):c.537T>G (p.His179Gln)	SNV	Likely Pathogenic	376607	rs876660821	GRCh37: 17:7578393-7578393 GRCh38: 17:7675075-7675075
19	TP53	NM_000546.6(TP53):c.374C>T (p.Thr125Met)	SNV	Likely Pathogenic	183748	rs786201057	GRCh37: 17:7579313-7579313 GRCh38: 17:7675995-7675995
20	TP53	NM_000546.6(TP53):c.403T>G (p.Cys135Gly)	SNV	Likely Pathogenic	376563	rs1057519975	GRCh37: 17:7578527-7578527 GRCh38: 17:7675209-7675209
21	TP53	NM_000546.6(TP53):c.451C>A (p.Pro151Thr)	SNV	Likely Pathogenic	12369	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
22	TP53	NM_000546.6(TP53):c.832C>G (p.Pro278Ala)	SNV	Likely Pathogenic	376645	rs17849781	GRCh37: 17:7577106-7577106 GRCh38: 17:7673788-7673788
23	PTEN	NM_000314.8(PTEN):c.389G>T (p.Arg130Leu)	SNV	Likely Pathogenic	376509	rs121909229	GRCh37: 10:89692905-89692905 GRCh38: 10:87933148-87933148
24	TP53	NM_000546.6(TP53):c.743G>T (p.Arg248Leu)	SNV	Likely Pathogenic	230253	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
25	TP53	NM_000546.6(TP53):c.584T>A (p.Ile195Asn)	SNV	Likely Pathogenic	376618	rs760043106	GRCh37: 17:7578265-7578265 GRCh38: 17:7674947-7674947
26	TP53	NM_000546.6(TP53):c.535C>T (p.His179Tyr)	SNV	Likely Pathogenic	127815	rs587780070	GRCh37: 17:7578395-7578395 GRCh38: 17:7675077-7675077
27	TP53	NM_000546.6(TP53):c.731G>A (p.Gly244Asp)	SNV	Likely Pathogenic	372785	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
28	TP53	NM_000546.6(TP53):c.742C>G (p.Arg248Gly)	SNV	Likely Pathogenic	376652	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
29	TP53	NM_000546.6(TP53):c.578A>C (p.His193Pro)	SNV	Likely Pathogenic	376612	rs786201838	GRCh37: 17:7578271-7578271 GRCh38: 17:7674953-7674953
30	PTPN11	NM_002834.5(PTPN11):c.227A>G (p.Glu76Gly)	SNV	Likely Pathogenic	13338	rs121918465	GRCh37: 12:112888211-112888211 GRCh38: 12:112450407-112450407
31	EGFR	NM_005228.5(EGFR):c.2582T>C (p.Leu861Pro)	SNV	Likely Pathogenic	376145	rs121913444	GRCh37: 7:55259524-55259524 GRCh38: 7:55191831-55191831
32	EGFR	NM_005228.5(EGFR):c.2582T>G (p.Leu861Arg)	SNV	Likely Pathogenic	45287	rs121913444	GRCh37: 7:55259524-55259524 GRCh38: 7:55191831-55191831
33	PPP6C	NM_002721.5(PPP6C):c.790C>T (p.Arg264Cys)	SNV	Likely Pathogenic	376508	rs763733111	GRCh37: 9:127912080-127912080 GRCh38: 9:125149801-125149801
34	DDR2	NM_006182.4(DDR2):c.716T>G (p.Leu239Arg)	SNV	Likely Pathogenic	376141	rs578015216	GRCh37: 1:162729630-162729630 GRCh38: 1:162759840-162759840
35	PTPN11	NM_002834.5(PTPN11):c.227A>C (p.Glu76Ala)	SNV	Likely Pathogenic	13339	rs121918465	GRCh37: 12:112888211-112888211 GRCh38: 12:112450407-112450407
36	EPHA2	NM_004431.5(EPHA2):c.1171G>C (p.Gly391Arg)	SNV	Likely Pathogenic	376146	rs34192549	GRCh37: 1:16464489-16464489 GRCh38: 1:16137994-16137994
37	EGFR	NM_005228.5(EGFR):c.2240T>C (p.Leu747Ser)	SNV	Likely Pathogenic	45236	rs397517097	GRCh37: 7:55242470-55242470 GRCh38: 7:55174777-55174777
38	EPHA2	NM_004431.5(EPHA2):c.1171G>A (p.Gly391Arg)	SNV	Likely Pathogenic	259386	rs34192549	GRCh37: 1:16464489-16464489 GRCh38: 1:16137994-16137994
39	PIK3CA	NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val)	SNV	Likely Pathogenic	376479	rs1057519930	GRCh37: 3:178916930-178916930 GRCh38: 3:179199142-179199142
40	CDKN2A	NM_000077.5(CDKN2A):c.340C>A (p.Pro114Thr)	SNV	Likely Pathogenic	376382	rs104894104	GRCh37: 9:21971018-21971018 GRCh38: 9:21971019-21971019
41	CDKN2A	NM_000077.5(CDKN2A):c.341C>A (p.Pro114His)	SNV	Likely Pathogenic	376383	rs121913386	GRCh37: 9:21971017-21971017 GRCh38: 9:21971018-21971018
42	PIK3CA	NM_006218.4(PIK3CA):c.452T>C (p.Val151Ala)	SNV	Likely Pathogenic	873163	rs1724363237	GRCh37: 3:178917577-178917577 GRCh38: 3:179199789-179199789
43	ALK	NM_004304.5(ALK):c.4472A>G (p.Lys1491Arg)	SNV	Likely Pathogenic	133474	rs1881420	GRCh37: 2:29416481-29416481 GRCh38: 2:29193615-29193615
44	ALK	NM_004304.5(ALK):c.4587C>G (p.Asp1529Glu)	SNV	Likely Pathogenic	133476	rs1881421	GRCh37: 2:29416366-29416366 GRCh38: 2:29193500-29193500
45	CDKN2A	NM_000077.5(CDKN2A):c.47_50del (p.Leu16fs)	MICROSAT	Likely Pathogenic	142061	rs587782206	GRCh37: 9:21974777-21974780 GRCh38: 9:21974778-21974781
46	CDKN2A	NM_000077.5(CDKN2A):c.292C>T (p.His98Tyr)	SNV	Likely Pathogenic	419560	rs1064793953	GRCh37: 9:21971066-21971066 GRCh38: 9:21971067-21971067
47	ALK	NM_004304.5(ALK):c.4381A>G (p.Ile1461Val)	SNV	Likely Pathogenic	133472	rs1670283	GRCh37: 2:29416572-29416572 GRCh38: 2:29193706-29193706
48	TP53	NM_000546.6(TP53):c.488A>G (p.Tyr163Cys)	SNV	Likely Pathogenic	127814	rs148924904	GRCh37: 17:7578442-7578442 GRCh38: 17:7675124-7675124
49	TP53	NM_000546.6(TP53):c.844C>T (p.Arg282Trp)	SNV	Likely Pathogenic	12364	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776
50	TP53	NM_000546.6(TP53):c.724T>A (p.Cys242Ser)	SNV	Likely Pathogenic	376579	rs1057519982	GRCh37: 17:7577557-7577557 GRCh38: 17:7674239-7674239

Cosmic variations for Lung Squamous Cell Carcinoma:

⁸ (show top 50) (show all 14419)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM101712070	ZRANB3	lung,NS,carcinoma,squamous cell carcinoma	c.3171G>C	p.V1057=	2:135200405-135200405	13
2	COSM131775319	ZRANB3	lung,NS,carcinoma,squamous cell carcinoma	c.1815G>C	p.V605=	2:135200405-135200405	13
3	COSM87596300	ZRANB3	lung,NS,carcinoma,squamous cell carcinoma	c.3177G>C	p.V1059=	2:135200405-135200405	13
4	COSM142228089	ZRANB3	lung,NS,carcinoma,squamous cell carcinoma	c.1566G>C	p.V522=	2:135200405-135200405	13
5	COSM142168947	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.-18G>C	p.?	7:89218278-89218278	13
6	COSM92052275	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.1662G>T	p.L554F	7:89334644-89334644	13
7	COSM142179137	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.3235C>T	p.Q1079*	7:89336466-89336466	13
8	COSM142183562	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.1361A>G	p.K454R	7:89334592-89334592	13
9	COSM142180477	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.1413G>T	p.L471F	7:89334644-89334644	13
10	COSM142169111	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.494G>A	p.C165Y	7:89333725-89333725	13
11	COSM142178407	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.734A>G	p.N245S	7:89333965-89333965	13
12	COSM92062218	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.1610A>G	p.K537R	7:89334592-89334592	13
13	COSM92044981	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.983A>G	p.N328S	7:89333965-89333965	13
14	COSM92017258	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.743G>A	p.C248Y	7:89333725-89333725	13
15	COSM92016873	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.232G>C	p.D78H	7:89218278-89218278	13
16	COSM92047471	ZNF804B	lung,NS,carcinoma,squamous cell carcinoma	c.3484C>T	p.Q1162*	7:89336466-89336466	13
17	COSM88573896	ZNF804A	lung,NS,carcinoma,squamous cell carcinoma	c.163G>T	p.A55S	2:184866420-184866420	13
18	COSM143615263	ZNF804A	lung,NS,carcinoma,squamous cell carcinoma	c.-93G>T	p.?	2:184866420-184866420	13
19	COSM135196993	ZNF598	lung,NS,carcinoma,squamous cell carcinoma	c.386G>A	p.R129H	16:2002647-2002647	13
20	COSM137961812	ZNF598	lung,NS,carcinoma,squamous cell carcinoma	c.386G>A	p.R129H	16:2002647-2002647	13
21	COSM94776745	ZNF521	lung,NS,carcinoma,squamous cell carcinoma	c.934T>A	p.C312S	18:25226984-25226984	13
22	COSM131483085	ZNF521	lung,NS,carcinoma,squamous cell carcinoma	c.934T>A	p.C312S	18:25226984-25226984	13
23	COSM140721616	ZNF521	lung,NS,carcinoma,squamous cell carcinoma	c.757C>T	p.P253S	18:25226501-25226501	13
24	COSM94799739	ZNF521	lung,NS,carcinoma,squamous cell carcinoma	c.1417C>T	p.P473S	18:25226501-25226501	13
25	COSM131506553	ZNF521	lung,NS,carcinoma,squamous cell carcinoma	c.1417C>T	p.P473S	18:25226501-25226501	13
26	COSM140704568	ZNF521	lung,NS,carcinoma,squamous cell carcinoma	c.274T>A	p.C92S	18:25226984-25226984	13
27	COSM89756750	ZNF479	lung,NS,carcinoma,squamous cell carcinoma	c.1064G>T	p.C355F	7:57120351-57120351	13
28	COSM144163369	ZNF479	lung,NS,carcinoma,squamous cell carcinoma	c.779+33G>T	p.?	7:57120351-57120351	13
29	COSM90068315	ZNF479	lung,NS,carcinoma,squamous cell carcinoma	c.1064G>T	p.C355F	7:57120351-57120351	13
30	COSM106286350	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
31	COSM112397402	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
32	COSM123216142	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
33	COSM125618139	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
34	COSM124797288	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
35	COSM122109165	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
36	COSM86289413	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
37	COSM124886437	ZNF331	lung,NS,carcinoma,squamous cell carcinoma	c.108G>T	p.L36=	19:53571702-53571702	13
38	COSM101607526	ZMYM2	lung,NS,carcinoma,squamous cell carcinoma	c.1484G>T	p.C495F	13:20006558-20006558	13
39	COSM101586020	ZMYM2	lung,NS,carcinoma,squamous cell carcinoma	c.1484G>T	p.C495F	13:20006558-20006558	13
40	COSM143104196	ZMYM2	lung,NS,carcinoma,squamous cell carcinoma	c.1484G>T	p.C495F	13:20006558-20006558	13
41	COSM120263221	ZIC4	lung,NS,carcinoma,squamous cell carcinoma	c.597G>A	p.T199=	3:147395943-147395943	13
42	COSM129142258	ZIC4	lung,NS,carcinoma,squamous cell carcinoma	c.747G>A	p.T249=	3:147395943-147395943	13
43	COSM85617592	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.138C>T	p.A46=	3:147410250-147410250	13
44	COSM85619505	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.99G>T	p.V33=	3:147410211-147410211	13
45	COSM85617600	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.587G>A	p.G196D	3:147410699-147410699	13
46	COSM85618817	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.244C>T	p.H82Y	3:147410356-147410356	13
47	COSM85617734	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.430C>G	p.P144A	3:147410542-147410542	13
48	COSM85619514	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.979A>T	p.T327S	3:147411091-147411091	13
49	COSM85618249	ZIC1	lung,NS,carcinoma,squamous cell carcinoma	c.64C>A	p.H22N	3:147410176-147410176	13
50	COSM125185026	ZFHX4	lung,NS,carcinoma,squamous cell carcinoma	c.2841G>T	p.L947=	8:76707874-76707874	13

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

⁶ (show top 50) (show all 61)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13957	1	101664084	102994090	Loss	COL11A1	Lung squamous cell carcinoma
2	18603	1	146800000	147200000	Loss		Lung squamous cell carcinoma
3	18604	1	146800000	147200000	Loss	NBPF15	Lung squamous cell carcinoma
4	18605	1	146800000	147200000	Loss	NBPF15	Lung squamous cell carcinoma
5	18606	1	146800000	147200000	Loss	PPIAL4E	Lung squamous cell carcinoma
6	47066	10	89540134	89615643	Loss	PTEN	Lung squamous cell carcinoma
7	51887	11	132926079	134452384	Loss	ACAD8	Lung squamous cell carcinoma
8	58625	11	68821296	70110392	Gain	CCND1	Lung squamous cell carcinoma
9	58626	11	68821296	70110392	Gain	PPFIA1	Lung squamous cell carcinoma
10	79487	13	72396304	72490843	Loss		Lung squamous cell carcinoma
11	89148	15	100100000	100300000	Loss	OR4F15	Lung squamous cell carcinoma
12	89149	15	100100000	100300000	Loss	OR4F4	Lung squamous cell carcinoma
13	89150	15	100100000	100300000	Loss	OR4F6	Lung squamous cell carcinoma
14	105616	16	80626349	81449546	Loss		Lung squamous cell carcinoma
15	107157	17	12394069	12459756	Loss		Lung squamous cell carcinoma
16	118123	17	7571720	7590868	Mutation	TP53	Lung squamous cell carcinoma
17	122933	18	64017241	75522477	Loss	CD226	Lung squamous cell carcinoma
18	122934	18	64017241	75522477	Loss	MBP	Lung squamous cell carcinoma
19	122935	18	64017241	75522477	Loss	RTTN	Lung squamous cell carcinoma
20	122936	18	64017241	75522477	Loss	SOCS6	Lung squamous cell carcinoma
21	128995	19	43840068	44336812	Gain	AKT2	Lung squamous cell carcinoma
22	128996	19	43840068	44336812	Gain	ECH1	Lung squamous cell carcinoma
23	130187	19	47900000	48300000	Loss	PSG1	Lung squamous cell carcinoma
24	130188	19	47900000	48300000	Loss	PSG11	Lung squamous cell carcinoma
25	130189	19	47900000	48300000	Loss	PSG2	Lung squamous cell carcinoma
26	130190	19	47900000	48300000	Loss	PSG3	Lung squamous cell carcinoma
27	130191	19	47900000	48300000	Loss	PSG6	Lung squamous cell carcinoma
28	130192	19	47900000	48300000	Loss	PSG7	Lung squamous cell carcinoma
29	130193	19	47900000	48300000	Loss	PSG8	Lung squamous cell carcinoma
30	131640	19	55600000	55700000	Gain	ASPDH	Lung squamous cell carcinoma
31	131641	19	55600000	55700000	Gain	EMC10	Lung squamous cell carcinoma
32	131642	19	55600000	55700000	Gain	GARIN5A	Lung squamous cell carcinoma
33	131643	19	55600000	55700000	Gain	JOSD2	Lung squamous cell carcinoma
34	131644	19	55600000	55700000	Gain	MYBPC2	Lung squamous cell carcinoma
35	131645	19	55600000	55700000	Gain	NAPSA	Lung squamous cell carcinoma
36	131646	19	55600000	55700000	Gain	NR1H2	Lung squamous cell carcinoma
37	131647	19	55600000	55700000	Gain	POLD1	Lung squamous cell carcinoma
38	131648	19	55600000	55700000	Gain	SPIB	Lung squamous cell carcinoma
39	149556	11	35116992	35210525	Loss	CD44	Lung squamous cell carcinoma
40	149667	2	91000000	91500000	Loss	GGT8P	Lung squamous cell carcinoma
41	149668	2	91000000	91500000	Loss		Lung squamous cell carcinoma
42	172539	3	183473858	183941579	Gain	SOX2	Lung squamous cell carcinoma
43	172540	3	183473858	183941579	Gain	TP63	Lung squamous cell carcinoma
44	179006	3	84414538	85858393	Loss	POU1F1	Lung squamous cell carcinoma
45	181932	4	130278523	134426567	Loss	PLK4	Lung squamous cell carcinoma
46	185649	4	20391110	20848036	Loss	BST1	Lung squamous cell carcinoma
47	185650	4	20391110	20848036	Loss	PI4K2B	Lung squamous cell carcinoma
48	185651	4	20391110	20848036	Loss	SLIT2	Lung squamous cell carcinoma
49	191445	5	1	1510601	Gain	TERT	Lung squamous cell carcinoma
50	202010	5	76066702	76539988	Loss	HTR1A	Lung squamous cell carcinoma

Sources

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Sources

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 48)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.91	TP53 PIK3CA KRAS HRAS EGFR
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.66	EGFR HRAS KRAS PIK3CA TP53
3	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.6	TP53 PIK3CA KRAS HRAS EGFR
4	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.54	EGFR HRAS KRAS PIK3CA TP53
5	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.39	PIK3CA KRAS HRAS EGFR
6	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.37	PIK3CA KRAS HRAS EGFR
7	MAPK signaling pathway ⁷⁴	12.35	TP53 KRAS HRAS EGFR
8	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.34	TP53 PIK3CA KRAS HRAS EGFR
9	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.27	TP53 PIK3CA KRAS HRAS EGFR
10	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.21	EGFR HRAS KRAS PIK3CA TP53
11	Ras signaling ⁷⁴	12.2	PIK3CA KRAS HRAS EGFR
12	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.19	PIK3CA KRAS HRAS EGFR
13	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.14	EGFR HRAS KRAS PIK3CA TP53
14	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.13	TP53 PIK3CA KRAS HRAS
15	Signaling by EGFR in Cancer ⁶⁶ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁶ Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁶ EGFR interacts with phospholipase C-gamma ⁶⁶ EGFR-dependent Endothelin signaling events ⁶¹ GRB2 events in EGFR signaling ⁶⁶ SHC1 events in EGFR signaling ⁶⁶ Signaling by EGFRvIII in Cancer ⁶⁶ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁶	12.03	PIK3CA KRAS HRAS EGFR
16	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.01	PIK3CA KRAS HRAS EGFR
17	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	11.97	PIK3CA KRAS HRAS EGFR
18	Gastrin signaling pathway ⁷⁴	11.9	PIK3CA KRAS HRAS EGFR
19	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.89	PIK3CA KRAS HRAS EGFR
20	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.87	PIK3CA KRAS HRAS
21	Signaling by Erythropoietin ⁶⁶ Show member pathways EPO signaling pathway ⁶¹ Erythropoietin activates Phosphoinositide-3-kinase (PI3K) ⁶⁶ Erythropoietin activates Phospholipase C gamma (PLCG) ⁶⁶ Erythropoietin activates RAS ⁶⁶ Erythropoietin activates STAT5 ⁶⁶	11.84	HRAS KRAS PIK3CA
22	FGFR1 mutant receptor activation ⁶⁶ Show member pathways Signaling by cytosolic FGFR1 fusion mutants ⁶⁶ Signaling by FGFR1 in disease ⁶⁶ Signaling by plasma membrane FGFR1 fusions ⁶⁶	11.82	PIK3CA KRAS HRAS
23	Signaling by PDGF ⁶⁶ Show member pathways Downstream signal transduction ⁶⁶	11.8	PIK3CA KRAS HRAS
24	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.77	TP53 PIK3CA HRAS
25	MAPK Signaling: Oxidative Stress ⁶⁵	11.74	KRAS NFE2L2 TP53
26	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.74	HRAS KRAS PIK3CA
27	DAP12 interactions ⁶⁶ Show member pathways DAP12 signaling ⁶⁶	11.71	PIK3CA KRAS HRAS
28	DNA damage response (only ATM dependent) ⁷⁴	11.71	TP53 PIK3CA KRAS HRAS
29	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.66	PIK3CA KRAS HRAS EGFR
30	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.62	TP53 PIK3CA HRAS
31	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.61	PIK3CA KRAS HRAS
32	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.58	KRAS HRAS EGFR
33	Signaling by PDGFR in disease ⁶⁶ Show member pathways Signaling by cytosolic PDGFRA and PDGFRB fusion proteins ⁶⁶ Signaling by membrane-tethered fusions of PDGFRA or PDGFRB ⁶⁶ Signaling by PDGFRA extracellular domain mutants ⁶⁶ Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants ⁶⁶	11.52	PIK3CA KRAS HRAS
34	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.46	TP53 PIK3CA KRAS HRAS
35	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.43	KRAS HRAS EGFR
36	Kisspeptin/kisspeptin receptor system in the ovary ⁷⁴	11.36	PIK3CA KRAS HRAS
37	a6b1 and a6b4 Integrin signaling ⁶¹	11.34	PIK3CA HRAS EGFR
38	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.22	PIK3CA KRAS HRAS
39	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11.15	KRAS HRAS EGFR
40	Transcription_Transcription factor Tubby signaling pathways ²²	11.15	TP53 KRAS HRAS EGFR
41	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	11.1	EGFR HRAS KRAS
42	G-protein signaling_K-RAS regulation pathway ²²	11.08	EGFR KRAS PIK3CA
43	Bladder cancer ⁷⁴	11.06	TP53 KRAS HRAS EGFR
44	Head and neck squamous cell carcinoma ⁷⁴	10.96	TP53 PIK3CA NFE2L2 KRAS HRAS EGFR
45	ERK pathway in Huntington's disease ⁷⁴	10.87	HRAS EGFR
46	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.76	KRAS HRAS
47	Aryl hydrocarbon receptor pathway ⁷⁴	10.73	NFE2L2 KRAS HRAS EGFR
48	Relationship between inflammation, COX-2 and EGFR ⁷⁴	10.67	PIK3CA EGFR

Sources

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.26	TP53 NFE2L2
2	positive regulation of miRNA maturation	GO:1903800	9.16	TP53 EGFR
3	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	8.92	TP53 NFE2L2